Zepbound beats Wegovy for weight loss
Digest more
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated and prescribed. Glass points out that obesity is a complex condition, and people with obesity often have other health issues as well, related to the heart, kidney, and liver. “It’s not just about weight,” he says.
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those ... the most commonly reported side effects for both Zepound and Wegovy were gastrointestinal-related and ...
While initially developed to treat Type 2 diabetes, GLP-1 drugs have surged in popularity for their ability to drive substantial weight loss. Demand for these therapies has skyrocketed in recent ...